Alvaro Ingles Russo Garces

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2429497/publications.pdf

Version: 2024-02-01

933447 1199594 12 332 10 12 citations g-index h-index papers 12 12 12 828 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors. Clinical Cancer Research, 2020, 26, 4777-4784.	7. O	31
2	Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer. Expert Opinion on Investigational Drugs, 2019, 28, 695-708.	4.1	38
3	Current and emerging systemic therapies for cutaneous metastatic melanoma. Expert Opinion on Pharmacotherapy, 2019, 20, 1135-1152.	1.8	33
4	Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors. European Journal of Cancer, 2018, 89, 56-63.	2.8	60
5	A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials. European Journal of Cancer, 2018, 104, 32-38.	2.8	15
6	Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. Annals of Oncology, 2018, 29, 1918-1925.	1.2	26
7	Targeting ATR in cancer medicine. Current Problems in Cancer, 2017, 41, 302-315.	2.0	43
8	Breast cancer-associated venous thromboembolism: A case–control study. Breast, 2016, 28, 84-88.	2.2	6
9	A phase I study of mTOR inhibitor everolimus in association with cisplatin and radiotherapy for the treatment of locally advanced cervix cancer: PHOENIX I. Cancer Chemotherapy and Pharmacology, 2016, 78, 101-109.	2.3	23
10	Exploiting HPV-Induced Carcinogenesis for a Rational Drug Development in Cervical Cancer. Current Cancer Drug Targets, 2016, 16, 249-260.	1.6	3
11	Treatment of ovarian cancer beyond chemotherapy: Are we hitting the target?. Cancer Chemotherapy and Pharmacology, 2015, 75, 221-234.	2.3	29
12	Coronary heart disease risk assessment in HIV-infected patients: a comparison of Framingham, PROCAM and SCORE risk assessment functions. International Journal of Clinical Practice, 2010, 64, 739-745.	1.7	25